Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.42 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.53 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5875130 | 1.00 | TSHR (0.53) | TSHRNAPRTTP53EGLN1EGLN3 | |
| Fumaric Acid SCHEMBL1968079 | 1.00 | TSHR (0.53) | TSHRNAPRTTP53EGLN1EGLN3 | |
| Fumaric Acid SCHEMBL9762549 | 1.00 | TSHR (0.53) | TSHRNAPRTTP53EGLN1EGLN3 | |
| Fumaric Acid SCHEMBL9761371 | 1.00 | TSHR (0.53) | TSHRNAPRTTP53EGLN1EGLN3 | |
| Maleic Acid SCHEMBL3669578 | 1.00 | TSHR (0.53) | TSHRNAPRTTP53EGLN1EGLN3 | |
| Maleic Acid SCHEMBL1968070 | 1.00 | TSHR (0.53) | TSHRNAPRTTP53EGLN1EGLN3 | |
| Fumaric Acid SCHEMBL9762551 | 1.00 | TSHR (0.53) | TSHRNAPRTTP53EGLN1EGLN3 | |
| Fumaric Acid SCHEMBL20184192 | 0.97 | TSHR (0.50) | TSHRNAPRTTP53EGLN1EGLN3 | |
| Maleic Acid SCHEMBL27512927 | 0.88 | TSHR (0.60) | TSHRNAPRTTP53EGLN1EGLN3 | |
| Fumaric Acid SCHEMBL27312490 | 0.88 | TSHR (0.60) | TSHRNAPRTTP53EGLN1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707787-A | Method for synthesizing 4-alkylpyridine compound by continuous light flow | 陕西师范大学 | 2025-03-28 | — | — | CN | claimed |
| US-12202827-B2 | Aldosterone synthase inhibitor | DAMIAN PHARMA AG (CH) | 2025-01-21 | — | — | US | claimed |
| CN-108707202-A | A kind of new and effective polymerization inhibitor and its application method for preventing alpha-olefin polymerization | 碳氢联合科技（北京）有限公司 | 2018-10-26 | — | — | CN | claimed |
| CN-104254535-B | Substituted pyrazolo [1,5 a] pyridine, its prepare and be used as the application of medicine | 埃斯蒂文博士实验室股份有限公司 | 2017-07-14 | — | — | CN | claimed |
| CN-103509029-B | Phenanthro-quinoline in western pyridine alcaloid-derivatives and salt thereof and their preparation, Antiphytoviral and antitumour activity | NANKAI UNIVERSITY (CN) | 2016-04-20 | — | — | CN | claimed |
| EP-2817309-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-12-31 | — | — | EP | claimed |
| CN-104254535-A | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR | 2014-12-31 | — | — | CN | claimed |
| CN-103509029-A | Phenanthroquinolizidine alkaloid derivatives and salts thereof, and preparation, anti-plant virus activity and anti-cancer activity of phenanthroquinolizidine alkaloid derivatives and salts thereof | UNIV NANKAI | 2014-01-15 | — | — | CN | claimed |
| WO-2013124341-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2013-08-29 | — | — | WO | claimed |
| EP-0397613-A2 | Pharmacologically active aminoimidazopyridines | DOMPE' FARMACEUTICI S.p.A. (IT) | 1990-11-14 | — | — | EP | claimed |
| WO-1988009783-A1 | POLYMERIC ULTRAVIOLET LIGHT ABSORBERS | BIOPOLYMERS LIMITED (AU) | 1988-12-15 | — | — | WO | claimed |
| CN-119707787-B | Method for synthesizing 4-alkylpyridine compound by continuous light flow | 陕西师范大学 | 2025-09-19 | — | — | CN | disclosed |
| CN-119707787-A | Method for synthesizing 4-alkylpyridine compound by continuous light flow | 陕西师范大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-119707787-A | Method for synthesizing 4-alkylpyridine compound by continuous light flow | 陕西师范大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20230090337-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPERAZIN-1 -YL)-2-(1,3-DIMETHYL-1 HPYRAZOL-4-YL)-3H- IMIDAZO[4,5-B]PYRIDINE | ELLIPSES PHARMA LTD (GB) | 2023-03-23 | — | — | US | disclosed |
| CN-87106804-A | Imidazopyridine derivatives, the pharmaceutical compositions that contains imidazopyridine derivatives and their preparation method | — | 1988-05-18 | — | — | CN | disclosed |
| US-4448779-A | 5-O-CYANOBENZYL-4,5,6,7-TETRAHYDROTHIENO(3,2-C)PYRIDINE | SANOFI (FR) | 1984-05-15 | — | — | US | disclosed |
| US-4400384-A | BLOOD PLATELET ANTICOAGULANTS, REDUCED SIDE EFFECTS | SANOFI, S.A. (FR) | 1983-08-23 | — | — | US | disclosed |
| US-4321266-A | 5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-C] pyridine | SANOFI (FR) | 1982-03-23 | — | — | US | disclosed |
| US-4145434-A | TETRACYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF MATTER | AKZONA INCORPORATED (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090337-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPERAZIN-1 -YL)-2-(1,3-DIMETHYL-1 HPYRAZOL-4-YL)-3H- IMIDAZO[4,5-B]PYRIDINE | FLT3, AURKC, AURKA | SLC6A2 4727/4885MEN1 1864/4885KMT2A 770/4885 |
| US-12202827-B2 | Aldosterone synthase inhibitor | CYP21A2, CYP17A1, CYP11B1 | SLC6A2 678/4885MEN1 1049/4885KMT2A 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.